Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 11:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Atherosclerotic Cardiovascular Disease (ASCVD) Clear all
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD)
Interventions
Pelacarsen, Placebo, Inclisiran
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
35
States / cities
Birmingham, Alabama • Sun City West, Arizona • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 21, 2026, 11:12 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Overweight, Obesity, Heart Failure (HF), Atherosclerotic Cardiovascular Disease (ASCVD), Primary Prevention
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
45 Years and older
Enrollment
285,327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced May 21, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions
bempedoic acid, placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
779 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Clearwater, Florida • Georgetown, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2020 · Synced May 21, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia, ASCVD, High Cholesterol
Interventions
Combination Therapy, Monotherapy obicetrapib, Monotherapy ezetimibe, Combination Therapy placebo, Obicetrapib Placebo, Ezetimibe Placebo
Combination Product · Drug · Other
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
45
States / cities
Gilbert, Arizona • Jacksonville, Florida • Port Orange, Florida + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced May 21, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions
bempedoic acid
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Tampa, Florida • Louisville, Kentucky • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 28, 2021 · Synced May 21, 2026, 11:12 PM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
ASCVD
Interventions
Not listed
Lead sponsor
Amgen
Industry
Eligibility
40 Years to 99 Years
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
143
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced May 21, 2026, 11:12 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced May 21, 2026, 11:12 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Interventions
Muvalaplin, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
10,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
121
States / cities
Gilbert, Arizona • Phoenix, Arizona • Sun City West, Arizona + 99 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 21, 2026, 11:12 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
206
States / cities
Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 158 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced May 21, 2026, 11:12 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
AZD0780, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
3,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
101
States / cities
Huntsville, Alabama • Irondale, Alabama • Mobile, Alabama + 92 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 11:12 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Interventions
Lepodisiran Sodium, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
17,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
222
States / cities
Birmingham, Alabama • Daphne, Alabama • Dothan, Alabama + 171 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 21, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
43
States / cities
Little Rock, Arkansas • Los Angeles, California • Greenwich, Connecticut + 32 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced May 21, 2026, 11:12 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
ASCVD, LDL-C
Interventions
Care Champion Intervention
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced May 21, 2026, 11:12 PM EDT
Not yet recruiting Not applicable Interventional
View directory record Official record
Conditions
ASCVD, Diabetes
Interventions
SMS (Initial Outreach), Secure Portal Message (Initial Outreach), Non-secure Email (Initial Outreach), SMS (Follow-up for Non-responders), Secure Portal Message (Follow-up for Non-responders), Non-secure Email (Follow-up for Non-responders)
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
22,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pleasant Hill, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced May 21, 2026, 11:12 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Obicetrapib, Placebo
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years and older
Enrollment
9,541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
199
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 161 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced May 21, 2026, 11:12 PM EDT
Active, not recruiting Phase 4 Interventional
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced May 21, 2026, 11:12 PM EDT
Not yet recruiting No phase listed Observational
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Coronary Artery Calcium Scan, Carotid Artery Ultrasound, Lipoprotein(a) Measurement, Vascular Function Testing
Diagnostic Test
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 21, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Statin Adverse Reaction
Interventions
bempedoic acid, placebo
Drug · Other
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
52
States / cities
Gilbert, Arizona • Anaheim, California • Long Beach, California + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced May 21, 2026, 11:12 PM EDT
Not yet recruiting Not applicable Interventional
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Coronary Artery Calcification
Interventions
AI-Detected CAC Notification and Care Facilitation
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 74 Years
Enrollment
120,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Pleasanton, California • Stanford, California + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced May 21, 2026, 11:12 PM EDT
Recruiting Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease, Atherosclerotic Cardiovascular Disease in Patients With ESKD
Interventions
CSL300, Placebo
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
2,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
163
States / cities
Decatur, Alabama • Huntsville, Alabama • Montgomery, Alabama + 118 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 21, 2026, 11:12 PM EDT